PRINCETON, N.J., 2021年3月29日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT）は、CERT), a global leader in biosimulation, today announced the appointments of Stephen Duffull, Ph.D., as a Senior Scientific Advisor and Mark Sale, M.D., as Vice President in the Integrated Drug Development (IDD) team.
“We are pleased to welcome Steve and Mark to Certara as we continue to broaden our company’s industry leading scientific expertise in pharmacometrics,” said Patrick Smith, PharmD, president of Integrated Drug Development at Certara. “We look forward to their contributions towards our efforts in accelerating the development of medicines by applying state-of-the-art quantitative approaches.”
In his new role, Dr. Duffull will provide scientific direction to technically complex projects and help shape the company’s scientific strategy by driving innovation of its pharmacometrics applications and by fostering optimal integration of its different quantitative capabilities. As one of the leading pharmacometricians in academia, Dr. Duffull brings 25 years of experience in quantitative pharmacology to Certara and has served as a Professor of Clinical Pharmacy at the University of Otago in Dunedin, New Zealand since 2006. His research and extensive scientific publication record cover a range of research topics, including the development of mechanistic models for complex pharmacological systems and the implementation of optimal design to improve clinical studies. Dr. Duffull earned his master’s degree in clinical pharmacy and a Ph.D. in pharmacometrics and Bayesian statistics from the University of Otago.
As a pharmaceutical industry veteran, Dr. Sale brings more than 30 years of experience in modeling and simulation to Certara. In his new role in the IDD team, he will partner with Certara’s clients to utilize pharmacometrics to strengthen their drug development programs. Dr. Sale has extensive experience conducting advanced pharmacometrics analyses across diverse therapeutic areas and developing novel machine learning methods to accelerate drug development. He received his M.D. from The Ohio State University and an M.A. in Biostatistics from Georgetown University. Dr. Sale completed a fellowship in clinical pharmacology at Stanford University and was an assistant professor of medicine and pharmacology at Georgetown University.